Therapeutic vaccines for aggressive B-cell lymphoma

References

• Xie Y, Pittaluga S, Jaffe ES. The histological classification of diffuse large B-cell lymphomas. Semin Hematol. 2015;52(2):57–66.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Connors JM. Treatment of aggressive non-Hodgkin’s lymphoma: a north American perspective. Oncology. 2005;19(4):26–34.
   PubMedGoogle Scholar
• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37(6):481–489.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68–83.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Xiao M, Au Q, et al. Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL. Cancer Immunol Res. 2019;7(4):644–657.
   PubMed Web of Science ®Google Scholar
• Guallar-Garrido S, Julián E. Bacillus Calmette-Guérin (BCG) therapy for bladder cancer: an update. Immunotargets Ther. 2020;9:1–11.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17(11):3520–3526.
   PubMed Web of Science ®Google Scholar
• Hammerich L, Marron TU, Upadhyay R, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25(5):814–824.
   PubMed Web of Science ®Google Scholar
• Li J, Song W, Czerwinski DK, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007;179(4):2493–2500.
   PubMed Web of Science ®Google Scholar
• Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood. 2009;113(15):3546–3552.
   PubMed Web of Science ®Google Scholar
• Goldstein MJ, Varghese B, Brody JD, et al. A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood. 2011;117(1):118–127.
   PubMed Web of Science ®Google Scholar
• Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R155.
   PubMed Web of Science ®Google Scholar
• Torigoe M, Sakata K, Ishii A, et al. Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. Clin Immunol. 2018;195:1–7.
   PubMed Web of Science ®Google Scholar
• Chung Y, Qin H, Kang CY, et al. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood. 2007;110(6):2013–2019.
   PubMed Web of Science ®Google Scholar
• Mattarollo SR, West AC, Steegh K, et al. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood. 2012;120(15):3019–3029.
   PubMed Web of Science ®Google Scholar
• Gadri Z, Kukulansky T, Bar-Or E, et al. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma. J Immunother. 2009;32(4):333–340.
   PubMed Web of Science ®Google Scholar
• Narayanan P, Lapteva N, Seethammagari M, et al. A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest. 2011;121(4):1524–1534.
   PubMed Web of Science ®Google Scholar
• Pradhan P, Leleux J, Liu J, et al. A simple, clinically relevant therapeutic vaccine shows long-term protection in an aggressive, delayed-treatment B lymphoma model. JCI Insight. 2017;2(22):16.
   Web of Science ®Google Scholar
• Chen Z, You L, Wang L, et al. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo. J Exp Clin Cancer Res. 2018;37(1):190.
   PubMed Web of Science ®Google Scholar
• Frank MJ, Khodadoust MS, Czerwinski DK, et al. Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: a phase I/II trial. J Exp Med. 2020;217(9):e20191712.
   PubMed Web of Science ®Google Scholar
• Marconato L, Frayssinet P, Rouquet N, et al. Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma. Clin Cancer Res. 2014;20(3):668–677.
   PubMed Web of Science ®Google Scholar
• Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–1271.
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment - tumorigenesis and therapy. Nat Rev Cancer. 2005;5(11):867–875.
   PubMed Web of Science ®Google Scholar
• Ma Y, Kepp O, Ghiringhelli F, et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol. 2010;22(3):113–124.
   PubMed Web of Science ®Google Scholar
• Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol. 2015;25(1):11–17.
   PubMed Web of Science ®Google Scholar
• Sistigu A, Viaud S, Chaput N, et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011;33(4):369–383.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118(6):1991–2001.
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–1059.
   PubMed Web of Science ®Google Scholar
• Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010;28(28):4324–4332.
   PubMed Web of Science ®Google Scholar
• Frank MJ, Reagan PM, Bartlett NL, et al. In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma. Cancer Discov. 2018;8(10):1258–1269.
   PubMed Web of Science ®Google Scholar
• Betting DJ, Yamada RE, Kafi K, et al. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J Immunother. 2009;32(6):622–631.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiseman GA, Maurer MJ, et al. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am J Hematol. 2013;88(7):589–593.
   PubMed Web of Science ®Google Scholar
• Zappasodi R, Pupa SM, Ghedini GC, et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res. 2010;70(22):9062–9072.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Zappasodi R, Carlo-Stella C, et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood. 2009;113(1):18–27.
   PubMed Web of Science ®Google Scholar
• Manzur S, Cohen S, Haimovich J, et al. Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma. Clin Exp Immunol. 2012;170(3):291–299.
   PubMed Web of Science ®Google Scholar
• Hömberg N, Adam C, Riedel T, et al. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma. Int J Cancer. 2014;135(12):2825–2833.
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chem Sci. 2016;7(2):842–854.
   PubMed Web of Science ®Google Scholar
• Bertinetti C, Zirlik K, Heining-Mikesch K, et al. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res. 2006;66(8):4496–4502.
   PubMed Web of Science ®Google Scholar
• Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine. 1999;18(9–10):765–777.
   PubMed Web of Science ®Google Scholar
• Lee CS, Bishop ES, Zhang R, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 2017;4(2):43–63.
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Caspar CB, Lambert SL, et al. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood. 2001;97(5):1370–1377.
   PubMed Web of Science ®Google Scholar
• Armstrong AC, Dermime S, Allinson CG, et al. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol. 2002;168(8):3983–3991.
   PubMed Web of Science ®Google Scholar
• Braun M, Jandus C, Maurer P, et al. Virus-like particles induce robust human T-helper cell responses. Eur J Immunol. 2012;42(2):330–340.
   PubMed Web of Science ®Google Scholar
• Lemke-Miltner CD, Blackwell SE, Yin C, et al. Antibody opsonization of a TLR9 agonist-containing virus-like particle enhances in situ immunization. J Immunol. 2020;204(5):1386–1394.
   PubMed Web of Science ®Google Scholar
• Chen YT, Chadburn A, Lee P, et al. Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proc Natl Acad Sci USA. 2010;107(7):3093–3098.
   PubMed Web of Science ®Google Scholar
• Cooper CD, Liggins AP, Ait-Tahar K, et al. PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. Leukemia. 2006;20(12):2172–2174.
   PubMed Web of Science ®Google Scholar
• Ait-Tahar K, Liggins AP, Collins GP, et al. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. Br J Haematol. 2009;146(4):396–407.
   PubMed Web of Science ®Google Scholar
• Ait-Tahar K, Liggins AP, Collins GP, et al. CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma. Haematologica. 2011;96(1):78–86.
   PubMed Web of Science ®Google Scholar
• Roberts WK, Livingston PO, Agus DB, et al. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 2002;99(10):3748–3755.
   PubMed Web of Science ®Google Scholar
• Palomba ML, Roberts WK, Dao T, et al. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res. 2005;11(1):370–379.
   PubMed Web of Science ®Google Scholar
• Li M, Yan Z, Han W, et al. Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies. Cell Immunol. 2006;239(2):136–143.
   PubMed Web of Science ®Google Scholar
• Milcent B, Josseaume N, Riller Q, et al. Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients. Cancer Immunol Immunother. 2019;68(10):1561–1572.
   PubMed Web of Science ®Google Scholar
• Liu Z, Xu-Monette ZY, Cao X, et al. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod Pathol. 2015;28(10):1297–1314.
   PubMed Web of Science ®Google Scholar
• Karkada M, Weir GM, Quinton T, et al. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. J Immunother. 2010;33(3):250–261.
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Bence-Bruckler I, Laneuville P, et al. Combination of DPX-Survivac, low dose cyclophosphamide, and pembrolizumab in recurrent/refractory DLBCL: the Spirel study. Blood. 2019;134(1):3236.
   Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–226.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Zhang M, Li J, et al. PD-1/PD-L1 blockade: have we found the key to unleash the antitumor immune response? Front Immunol. 2017;8:1597.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–221.
   PubMed Web of Science ®Google Scholar
• Nelde A, Walz JS, Kowalewski DJ, et al. HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. Oncoimmunology. 2017;6(3):e1219825.
   PubMed Web of Science ®Google Scholar
• Nielsen JS, Chang AR, Wick DA, et al. Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncoimmunology. 2017;6(7):e1321184.
   PubMed Web of Science ®Google Scholar
• Khodadoust MS, Olsson N, Wagar LE, et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature. 2017;543(7647):723–727.
   PubMed Web of Science ®Google Scholar
• Khodadoust MS, Olsson N, Chen B, et al. B-cell lymphomas present immunoglobulin neoantigens. Blood. 2019;133(8):878–881.
   PubMed Web of Science ®Google Scholar
• Huszthy PC, Gopalakrishnan RP, Jacobsen JT, et al. B cell receptor ligation induces display of V-region peptides on MHC class II molecules to T cells. Proc Natl Acad Sci USA. 2019;116(51):25850–25859.
   PubMed Web of Science ®Google Scholar
• Sun Z, Chen F, Meng F, et al. MHC class II restricted neoantigen: a promising target in tumor immunotherapy. Cancer Lett. 2017;392:17–25.
   PubMed Web of Science ®Google Scholar
• Nielsen JS, Sedgwick CG, Shahid A, et al. Toward personalized lymphoma immunotherapy: identification of common driver mutations recognized by patient CD8+ T cells. Clin Cancer Res. 2016;22(9):2226–2236.
   PubMed Web of Science ®Google Scholar
• Rajasagi M, Shukla SA, Fritsch EF, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014;124(3):453–462.
   PubMed Web of Science ®Google Scholar
• Nijland M, Veenstra RN, Visser L, et al. HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy? Oncoimmunology. 2017;6(4):e1295202.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Redd RA, Cader FZ, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018;36(10):942–950.
   PubMed Web of Science ®Google Scholar
• Alspach E, Lussier DM, Miceli AP, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019;574(7780):696–701.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Li J, Xia Y, et al. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019;7(1):272.
   PubMed Web of Science ®Google Scholar
• Adler LN, Jiang W, Bhamidipati K, et al. The other function: class II-restricted antigen presentation by B cells. Front Immunol. 2017;8:319.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Abdul-Ahad AK, Gordon J, et al. Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces. Br J Cancer. 1980;42(4):495–502.
   PubMed Web of Science ®Google Scholar
• Lynch RG, Graff RJ, Sirisinha S, et al. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA. 1972;69(6):1540–1544.
   PubMed Web of Science ®Google Scholar
• Park HJ, Neelapu SS. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol. 2008;142(2):179–191.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Kitamura K, Maloney DG, et al. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol. 1987;138(4):1289–1296.
   PubMed Web of Science ®Google Scholar
• Kwak LW, Young HA, Pennington RW, et al. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA. 1996;93(20):10972–10977.
   PubMed Web of Science ®Google Scholar
• Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327(17):1209–1215.
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma–long-term results of a clinical trial. Blood. 1997;89(9):3129–3135.
   PubMed Web of Science ®Google Scholar
• Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5(10):1171–1177.
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99(5):1517–1526.
   PubMed Web of Science ®Google Scholar
• Koç ON, Redfern C, Wiernik PH, et al. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J Immunother. 2010;33(2):178–184.
   PubMed Web of Science ®Google Scholar
• Inogès S, Rodrìguez-Calvillo M, Zabalegui N, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Nat Cancer Inst. 2006;98(18):1292–1301.
   PubMedGoogle Scholar
• Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011;29(20):2787–2794.
   PubMed Web of Science ®Google Scholar
• Redfern CH, Guthrie TH, Bessudo A, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin’s lymphoma resulting in durable clinical responses. J Clin Oncol. 2006;24(19):3107–3112.
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Vose JM, Czerwinski DK, et al. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2009;50(1):37–46.
   PubMed Web of Science ®Google Scholar
• Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009;27(18):3036–3043.
   PubMed Web of Science ®Google Scholar
• Levy R, Ganjoo KN, Leonard JP, et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol. 2014;32(17):1797–1803.
   PubMed Web of Science ®Google Scholar
• Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer. 2009;9(9):675–681.
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Singh G, Hermanson G, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 2002;62(20):5845–5852.
   PubMed Web of Science ®Google Scholar
• Weng WK, Czerwinski D, Timmerman J, et al. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004;22(23):4717–4724.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Xiao H, Liu Y, et al. Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol. 2010;185(9):5082–5092.
   PubMed Web of Science ®Google Scholar
• Thomas SK, Cha SC, Smith DL, et al. Phase I study of an active immunotherapy for asymptomatic phase lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer. 2018;18(1):187.
   PubMedGoogle Scholar
• Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002;2(12):920–932.
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel. 2000;65(1–2):271–284.
   PubMed Web of Science ®Google Scholar
• Beg S, Alharbi KS, Alruwaili NK, et al. Nanotherapeutic systems for delivering cancer vaccines: recent advances. Nanomedicine. 2020;15(15):1527–1537.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Baskar S, Gause BL, et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res. 2004;10(24):8309–8317.
   PubMed Web of Science ®Google Scholar
• Qu X, Yao C, Wang J, et al. Anti-CD30-targeted gold nanoparticles for photothermal therapy of L-428 Hodgkin’s cell. Int J Nanomed. 2012;7:6095–6103.
   PubMed Web of Science ®Google Scholar
• Setyawati MI, Tay CY, Bay BH, et al. Gold nanoparticles induced endothelial leakiness depends on particle size and endothelial cell origin. ACS Nano. 2017;11(5):5020–5030.
   PubMed Web of Science ®Google Scholar
• Peng F, Setyawati MI, Tee JK, et al. Nanoparticles promote in vivo breast cancer cell intravasation and extravasation by inducing endothelial leakiness. Nat Nanotechnol. 2019;14(3):279–286.
   PubMed Web of Science ®Google Scholar
• Munz C. Immune control and vaccination against the Epstein-Barr Virus in humanized mice. Vaccines. 2019;7(4):217.
   Web of Science ®Google Scholar
• Wojtak K, Perales-Puchalt A, Weiner DB. Novel synthetic DNA immunogens targeting latent Expressed antigens of Epstein-Barr Virus elicit potent cellular responses and inhibit tumor growth. Vaccines. 2019;7(2):44.
   Web of Science ®Google Scholar
• Zhao B, Zhang X, Krummenacher C, et al. Immunization with Fc-based recombinant Epstein-Barr virus gp350 elicits potent neutralizing humoral immune response in a BALB/c mice model. Front Immunol. 2018;9:932.
   PubMed Web of Science ®Google Scholar
• Bu W, Joyce MG, Nguyen H, et al. Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells. Immunity. 2019;50(5):1305.e6–1316.e6.
   Web of Science ®Google Scholar